Characteristics of allo-HSCT recipients with sufficient compared with suboptimal anti–RBD-S1 IgG (<100 BAU/mL) or nondetectable S1–IFN-γ after 2 doses of vaccinations
| . | Anti–RBD-S1 IgG<100 BAU/mL (n = 5) . | Anti–RBD-S1 IgG ≥100 BAU/mL (n = 45) . | OR* (95% CI) . | P† . | IFN-γ production <10 pg/mL (n = 14) . | IFN-γ production ≥10 pg/mL (n = 36) . | OR* (95% CI) . | P† . |
|---|---|---|---|---|---|---|---|---|
| Median age at vaccination, y (range) | 62 (31-71) | 53 (29-78) | 1.0 (0.9-1.0) | .63 | 61 (42-78) | 52.5 (29-75) | 0.96 (0.9-1.0) | .09 |
| Time after allo-HSCT <24 mo, n (%) | 3 (60) | 3 (7) | 21.0 (2.5-178.2) | .009 | 3 (21) | 3 (8) | 3.0 (0.5-17.3) | .22 |
| Sex female/male, n (%) | 1 (20)/4 (80) | 23 (51)/22 (49) | 4.2 (0.4-40.4) | .35 | 6 (43)/8 (57) | 18 (50)/18 (50) | 1.6 (0.4-4.6) | .65 |
| Vaccine (Pfizer-BionTech/Moderna), n (%) | 3 (60)/2 (40) | 29 (64)/16 (36) | 1.2 (0.2-8.0) | 1.00 | 8 (53)/7 (47) | 24 (69)/11 (31) | 1.5 (0.4-5.3) | .53 |
| Chronic GVHD, n (%) | 3 (60) | 15 (33) | 3.0 (0.5-6.8) | .34 | 6 (43) | 12 (33) | 1.5 (0.4-5.3) | .53 |
| Ongoing immunosuppressive treatment, n (%) | 2 (40) | 7 (16) | 3.6 (0.5-25.8) | .22 | 2 (14) | 7 (19) | 0.7 (0.1-3.8) | .67 |
| . | Anti–RBD-S1 IgG<100 BAU/mL (n = 5) . | Anti–RBD-S1 IgG ≥100 BAU/mL (n = 45) . | OR* (95% CI) . | P† . | IFN-γ production <10 pg/mL (n = 14) . | IFN-γ production ≥10 pg/mL (n = 36) . | OR* (95% CI) . | P† . |
|---|---|---|---|---|---|---|---|---|
| Median age at vaccination, y (range) | 62 (31-71) | 53 (29-78) | 1.0 (0.9-1.0) | .63 | 61 (42-78) | 52.5 (29-75) | 0.96 (0.9-1.0) | .09 |
| Time after allo-HSCT <24 mo, n (%) | 3 (60) | 3 (7) | 21.0 (2.5-178.2) | .009 | 3 (21) | 3 (8) | 3.0 (0.5-17.3) | .22 |
| Sex female/male, n (%) | 1 (20)/4 (80) | 23 (51)/22 (49) | 4.2 (0.4-40.4) | .35 | 6 (43)/8 (57) | 18 (50)/18 (50) | 1.6 (0.4-4.6) | .65 |
| Vaccine (Pfizer-BionTech/Moderna), n (%) | 3 (60)/2 (40) | 29 (64)/16 (36) | 1.2 (0.2-8.0) | 1.00 | 8 (53)/7 (47) | 24 (69)/11 (31) | 1.5 (0.4-5.3) | .53 |
| Chronic GVHD, n (%) | 3 (60) | 15 (33) | 3.0 (0.5-6.8) | .34 | 6 (43) | 12 (33) | 1.5 (0.4-5.3) | .53 |
| Ongoing immunosuppressive treatment, n (%) | 2 (40) | 7 (16) | 3.6 (0.5-25.8) | .22 | 2 (14) | 7 (19) | 0.7 (0.1-3.8) | .67 |